A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.

Clin Pharmacol Ther · 2025 · PMC11739751 · PMID 39328022

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

Further stratification by dosing cycles revealed a slight trend towards increased CRS with RO max % following dose one (Cycle 1 Day 1), no trend following dose two (Cycle 1 Day 8), and an increased trend following dose three (Cycle 1 Day 15) towards the higher tested RO max % range.

also in 2,443 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.